CD8A and neoplasm: Thus, although RIT HLA-I molecules may not show specific advantages under optimal antigen presentation conditions, they are expected to be more efficient in presenting TAP-independent peptides to CD8+ T cells in infection or tumor conditions involving TAP blockade.